RL
ANIP icon

Ruffer LLP’s ANI Pharmaceuticals ANIP Stock Holding History

Ruffer LLP’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.74M Buy
69,426
+9,235
+15% +$741K 0.2% 94
2026
Q1 		$4.64M Buy
+60,191
New +$4.7M 0.19% 75

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ruffer LLP's ANIP Position: Q2 2026 in Review

Ruffer LLP increased its ANI Pharmaceuticals (ANIP) stake by 15% in Q2 2026, buying an estimated $741K and bringing the position to 69,426 shares worth $5.74M. The position accounts for 0.2% of the portfolio, ranked #94.

Ruffer LLP first reported a position in ANIP in Q1 2026 and has held it in 2 quarters since. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Ruffer LLP held 69,426 shares of ANI Pharmaceuticals worth $5.74M as of Q2 2026.
  • Ruffer LLP bought 9,235 ANI Pharmaceuticals shares in Q2 2026, an estimated $741K.
  • ANI Pharmaceuticals made up 0.2% of Ruffer LLP's portfolio in Q2 2026, its #94 holding.
  • Ruffer LLP first reported a position in ANI Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Ruffer LLP's 13F filing for Q2 2026, filed 30 Jul 2026.